/

CABA

Cabaletta Bio, Inc.Closed

1.69−0.10 −5.59%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.67 −1.15%

Open

1.82

Prev close

1.79

Day range

1.591.82

52-week range

1.594.23

Volume

7.93M1.71×

Mkt cap

286.53M

P/E ttm

—

Fwd P/E

-1.42

EPS ttm

-1.51

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−60.05%

Price Chart

Yahoo Finance · delayed

CABAOct 13, 2026O 1.79H 1.82L 1.59C 1.69−0.10 (−5.59%)Vol 7.94M

SMA 502.65
SMA 2002.90

1Y change −27.16% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CABA Cabaletta Bio, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −16.34%
1 month: −38.10%
3 months: −36.70%
6 months: −48.16%
Year to date: −22.83%
1 year: −32.13%

Valuation & ownership

Market cap: 286.53M
Enterprise value: 87.14M
P/E (ttm): —
Forward P/E: -1.42
PEG ratio: —
Price / book: 1.35
Price / sales (ttm): —
EV / EBITDA: -0.47
EPS (ttm): -1.51
EPS (forward): -1.19
Beta (5y monthly): 3.48
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 169.55M
Float: 141.48M
Short % of float: 25.11%
Short ratio (days): 6.26
Held by insiders: 0.97%
Held by institutions: 94.42%
Avg volume (3m): 4.64M
50-day average: 2.67
200-day average: 2.90
52-week change: −32.13%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 25.7
vs 50-day SMA: −36.25%
vs 200-day SMA: −41.70%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 10.03%
Realised vol (20d, ann.): 63.0%
From 52-week high: −60.05%
From 52-week low: +6.29%

ANR

Analyst Consensus

8 analysts

Consensus

—

Mean target

13.25

+684.02% implied

Low 3.00Median 13.50High 30.00

Recommendation trend

Now8 / 2 / 0
1m ago8 / 2 / 0

Buy / hold / sell counts

DES

About Cabaletta Bio, Inc.

Yahoo Finance profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
Employees: 154
Headquarters: Philadelphia, PA, United States
Website: cabalettabio.com
Officers: Dr. Steven A. Nichtberger M.D. Co-Founder, Chairman, CEO & President

SEAS

Seasonality · CABA

2019–2026 · monthly returns

Strongest month Oct +33.72%Weakest month Mar −18.37%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	17.4	29.2	-19.0	11.2	26.4	-17.7	-13.8	16.0	-38.3	-12.0			−22.8%
2025	5.3	-24.5	-23.3	-4.7	41.7	-18.7	0.0	-4.6	61.4	54.3	-28.8	-14.8	−3.5%
2024	-9.8	11.7	-25.4	-37.6	-4.3	-26.6	-5.1	-20.7	-16.2	-24.8	7.6	-40.6	−90.0%
2023	31.8	-27.5	-6.4	25.5	-2.8	27.9	5.5	4.0	7.5	-6.3	12.6	41.4	+145.4%
2022	-20.3	-28.5	-6.0	-32.0	-7.2	-17.2	11.3	-19.1	-31.9	160.0	165.1	106.5	+144.1%
2021	4.4	-16.6	2.1	0.3	1.9	-24.2	-13.3	36.5	19.4	12.4	-15.3	-67.3	−69.6%
2020	17.6	-9.1	-51.1	-0.7	17.9	30.3	2.6	-7.7	2.7	6.7	28.6	-16.1	−10.7%
2019											30.5	2.0	+33.0%

INSD

Insider Activity · CABA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jan 20, 2026	Simon MarkDirector	Purchase at price 2.28 per share.	11.1K	$25.26K
Jan 20, 2026	Nichtberger StevenChief Executive Officer	Purchase at price 2.24 per share.	45K	$100.78K
Jan 20, 2026	Tomasello Shawn ClineDirector	Purchase at price 2.21 per share.	22.7K	$50.32K
Jan 20, 2026	Chang David J. M.D.Officer	Purchase at price 2.26 per share.	8.8K	$19.89K
Jan 20, 2026	Bollard Catherine M.D.Director	Purchase at price 2.27 per share.	4.4K	$9.98K
Jan 20, 2026	Binder GwendolynOfficer	Purchase at price 2.19 per share.	11.3K	$24.76K
Jan 20, 2026	Gerard MichaelGeneral Counsel	Purchase at price 2.27 per share.	6.6K	$14.98K
Jan 20, 2026	Gavel SteveOfficer	Purchase at price 2.26 per share.	22.2K	$50.22K

13F

Investors Holding CABA

latest 13F filings of 29 followed managers

Investors holding CABA
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$4.8M	0.01%	1.54M	−25%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CABA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CABA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cabaletta Bio, Inc.

Seasonality · CABA

Insider Activity · CABA

Congress Trades · CABA

Investors Holding CABA

Investors Holding CABA

Congress Trades · CABA

Seasonality · CABA

Insider Activity · CABA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Cabaletta Bio, Inc.

Financial Snapshot

Earnings & Dividends

News